126085-89-0

Usage

Uses

Used in Organic Synthesis:
3-Methyl-5-(tributylstannyl)isoxazole is used as a synthon for the construction of complex organic molecules, facilitating the introduction of the isoxazole ring into various organic compounds through substitution reactions.
Used in Medicinal Chemistry and Drug Discovery:
In the field of medicinal chemistry, 3-Methyl-5-(tributylstannyl)isoxazole is utilized as a valuable building block for the development of new pharmaceuticals, contributing to the synthesis of potential drug candidates with diverse biological activities.
Used in Chemical Research:
3-Methyl-5-(tributylstannyl)isoxazole is employed in chemical research to explore its reactivity and potential applications in the synthesis of novel compounds with specific properties, such as those with potential therapeutic or industrial uses.

Upstream product

• 79-24-3 Nitroethane 
• 994-89-8 tributylethynyltin 
• 7063-95-8 acetonitrile-N-oxide 
• 2909-38-8 m-chlorophenyl isocyanate 

Downstream Products

• 85903-37-3 3-Methyl-5-(2-pyridyl)isoxazole 
• 85903-38-4 3-Methyl-5-(3-pyridyl)isoxazole 
• 1008-75-9 3-methyl-5-phenylisoxazole 
• 126633-04-3 3-Methyl-5-(2-nitrophenyl)isoxazole 
• 136295-81-3 5-<2-(Methoxymethoxy)phenyl>-3-methylisoxazole 
• 157025-23-5 (6R,7R)-3-(3-Methyl-isoxazol-5-ylmethyl)-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 126085-92-5 5-iodo-3-methylisoxazole 
• 31301-36-7 3-Methyl-5-isoxazolyl phenyl ketone 
• 474706-05-3 4-(3-methylisoxazol-5-yl)-6-(3-trifluoromethyl-1-trityl-1H-pyrazol-4-yl)-quinoline 
• 1173176-99-2 methyl 2-methoxy-4-(3-methylisoxazol-5-yl)benzoate 
• 1235492-20-2 5-(2-methoxy-4-nitrophenyl)-3-methylisoxazole 

Relevant academic research and scientific papers

The synthesis of epiboxidine and related analogues as potential pharmacological agents

Methyl epiboxidine-N-carboxylate (8) was synthesized from 7 under reductive Heck conditions (Scheme 2). The C-C coupling of the new epiboxidine analog 9 with aryl and heteroaryl halides gave by hydroarylation C-aryl, N-(3-methylisoxazol-5-yl)-substituted

A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove

Proprotein convertase (PC) subtilisin kexin type 9 (PCSK9) inhibits the clearance of low density lipoprotein (LDL) cholesterol from plasma by directly interacting with the LDL receptor (LDLR). As the interaction promotes elevated plasma LDL cholesterol levels and a predisposition to cardiovascular disease (CVD), it has attracted much interest as a therapeutic target. While anti-PCSK9 monoclonal antibodies have been successful in the treatment of hypercholesteremia by decreasing CVD risk, their high cost and a requirement for injection have prohibited widespread use. The advent of an orally bioavailable small molecule inhibitor of the PCSK9-LDLR interaction is an attractive alternative, however efforts have been tempered as the binding interface is unfavourable for binding by small organic molecules. Despite its challenging nature, we report herein the discovery of compound 3f as a small molecule inhibitor of PCSK9. The kinase inhibitor nilotinib emerged from a computational screen that was applied to identify compounds that may bind to a cryptic groove within PCSK9 and proximal to the LDLR-binding interface. A subsequent in vitro PCSK9-LDLR binding assay established that nilotinib was a bona fide but modest inhibitor of the interaction (IC50 = 9.8 μM). Through multiple rounds of medicinal chemistry, 3f emerged as a lead-like molecule by demonstrating disruption of the PCSK9-LDLR interaction at nanomolar levels in vitro (IC50 = 537 nM) with no inhibitory activity (IC50 > 10 μM) against a small panel of kinases. Compound 3f restored LDL uptake by liver cells at sub-micromolar levels and demonstrated excellent bioavailability when delivered subcutaneously in mice. Most significantly, compound 3f lowered total cholesterol levels in the plasma of wild-type mice, thereby providing proof-of-concept that the notion of a small molecule inhibitor against PCSK9 is therapeutically viable.

PYRIDONE COMPOUND AS C-MET INHIBITOR

Disclosed in the present invention is a type of pyridone compounds as c-met inhibitors, and specifically disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

HETEROCYCLIC INHIBITORS OF PCSK9

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I): (I) wherein A, D and Q are described herein.

Discovery of potent and selective 8-fluorotriazolopyridine c-met inhibitors

The overexpression of c-Met and/or hepatocyte growth factor (HGF), the amplification of the MET gene, and mutations in the c-Met kinase domain can activate signaling pathways that contribute to cancer progression by enabling tumor cell proliferation, survival, invasion, and metastasis. Herein, we report the discovery of 8-fluorotriazolopyridines as inhibitors of c-Met activity. Optimization of the 8-fluorotriazolopyridine scaffold through the combination of structure-based drug design, SAR studies, and metabolite identification provided potent (cellular IC50 a mouse liver pharmacodynamic model.

BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula 1: wherein Het, X, R1 and R2 are as defined herein.

FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.